Entos Pharmaceuticals, an Edmonton, Canada-based biotech company that develops genetic medicines, received an investment from CureDuchenne Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to create a muscle-targeting therapeutic to deliver full-length dystrophin for the treatment of Duchenne muscular dystrophy (DMD).
Led by CEO John Lewis, Entos levarages the Fusogenix PLV platform, which is a delivery system that combines the aspects of viral and non-viral approaches. Using a completely new mechanism for intracellular delivery of RNA, DNA and gene editing therapies, Fusogenix PLV is suitable for a wide range of genetic medicines.
The company has partnered with global companies, such as Eli Lilly, to accelerate and expand the impact of its platform. It also has wholly owned U.S. and U.K. subsidiaries based in San Diego, California, and London, United Kingdom.
FinSMEs
22/05/2025